Insulin aspart biosimilar (Tonghua Dongbao Pharmaceutical)

门冬胰岛素生物类似药（通化东宝）

Report date: 2022/11/15 15:18:04

Base Information

Drug NameInsulin aspart biosimilar (Tonghua Dongbao Pharmaceutical)
Drug Alias Name门冬胰岛素生物仿制药（通化东宝）
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2021/10/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTonghua Dongbao Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMeitheal Pharmaceuticals IncTonghua Dongbao Pharmaceutical Co LtdNanjing King-Friend Biochemical Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AB05A10AD05
Related LinksN/A